Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease.
暂无分享,去创建一个
Philippe Hantraye | Maria-Joao Ribeiro | Marc Peschanski | Yves Samson | Marie Vidailhet | Frédéric Dollé | M. Vidailhet | Y. Samson | P. Remy | M. Peschanski | M. Ribeiro | J. Nguyen | F. Dollé | P. Hantraye | C. Loc’h | P. Césaro | Philippe Remy | Pierre Cesaro | Jean Paul Nguyen | Christian Loc'h | C. Dupel | M. Ponchant | Corinne Dupel | Michel Ponchant | C. Loc'h
[1] J. Rinne,et al. Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [18F]CFT PET Study , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[3] A. J. Stoessl,et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.
[4] J C Froment,et al. Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study , 1999, Movement disorders : official journal of the Movement Disorder Society.
[5] B. Långström,et al. Regulation of dopaminergic activity in early Parkinson's disease , 1999, Annals of neurology.
[6] P. Remy,et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD) , 1999, Movement disorders : official journal of the Movement Disorder Society.
[7] M. Fujita,et al. Comparison between the decrease of dopamine transporter and that of L‐DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models , 1999, Synapse.
[8] V. Oikonen,et al. Striatal uptake of a novel PET ligand, [18F]β‐CFT, is reduced in early Parkinson's disease , 1999, Synapse.
[9] E. Bézard,et al. Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach , 1998, Progress in Neurobiology.
[10] F. Vingerhoets,et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.
[11] W. J. Lorenz,et al. Performance evaluation of the whole-body PET scanner ECAT EXACT HR + , 1997 .
[12] T. Ishikawa,et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] D J Brooks,et al. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.
[14] N. Volkow,et al. Dopamine transporters decrease with age. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] M. Kuhar,et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[16] D J Brooks,et al. Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[17] Eileen O. Smith,et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.
[18] Vincent Frouin,et al. Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patients , 1995, Annals of neurology.
[19] J. Haycock,et al. Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? , 1995, Annals of neurology.
[20] C. Halldin,et al. Synthesis of 2β‐carbomethoxy‐3β‐(4‐[76Br]bromophenyl)tropane ([76Br]β‐CBT), a pet tracer for in vivo imaging of the dopamine uptake sites , 1995 .
[21] Y. Samson,et al. Peduncular 'Rubral' Tremor and Dopaminergic Denervation , 1995, Neurology.
[22] M Schulzer,et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.
[23] L. Metman,et al. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease , 1994, Neurology.
[24] C. Robertson,et al. Cerebral metabolism. , 1994, Neurosurgery clinics of North America.
[25] M Laruelle,et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Patlak,et al. Striatal 18F-DOPA Uptake: Absence of an Aging Effect , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[28] O. Hornykiewicz,et al. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. , 1993, Advances in neurology.
[29] M Schulzer,et al. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic , 1992, Annals of neurology.
[30] G L Brownell,et al. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism , 1992, Neuroreport.
[31] S. Kish,et al. Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.
[32] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[33] L. Parsons,et al. The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens , 1991, Journal of Neuroscience Methods.
[34] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[35] Yves Agid,et al. Parkinson's disease: pathophysiology , 1991, The Lancet.
[36] Alan C. Evans,et al. Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[37] Richard S. J. Frackowiak,et al. Striatal function in normal aging: Implications for Parkinson's disease , 1990, Annals of neurology.
[38] B. Mazoyer,et al. Physical Characteristics Of The Ecat 953b/31: A New High Resolution Brain Positron Tomograph , 1990, 1990 IEEE Nuclear Science Symposium Conference Record.
[39] C D Marsden,et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.
[40] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[41] A. Grace,et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.
[42] Y. Agid,et al. Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.
[43] Wade K. Smith,et al. Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.
[44] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[45] H. Tilson,et al. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage , 1988, Brain Research.
[46] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[47] C Nahmias,et al. Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.
[48] P. Rice,et al. The early diagnosis of Parkinson's disease. , 1984, Australian family physician.
[49] R. S. Sloviter,et al. Postmortem stability of norepinephrine, dopamine, and serotonin in rat brain 1 , 1977, Journal of neurochemistry.
[50] P. Mcgeer,et al. Aging and extrapyramidal function. , 1977, Archives of neurology.